Literature DB >> 23642560

Multiparametric magnetic resonance imaging of the prostate.

Jaime Araujo Oliveira Neto1, Daniella Braz Parente.   

Abstract

The multiparametric approach expanded the clinical applications for prostate magnetic resonance (MR) imaging to include not only staging but also a correlation with tumor aggressiveness. It can also help to guide biopsies, to achieve a higher tumor detection rate, and to better reflect the true Gleason grade. The improved accuracy provided by multiparametric MR imaging and a better understanding of the clinical significance of the imaging findings can pave the way to a more direct role of MR imaging in patient management.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23642560     DOI: 10.1016/j.mric.2013.01.004

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  6 in total

Review 1.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

Review 2.  Computer-aided Detection of Prostate Cancer with MRI: Technology and Applications.

Authors:  Lizhi Liu; Zhiqiang Tian; Zhenfeng Zhang; Baowei Fei
Journal:  Acad Radiol       Date:  2016-04-25       Impact factor: 3.173

3.  Molecular imaging and fusion targeted biopsy of the prostate.

Authors:  Baowei Fei; Peter T Nieh; Viraj A Master; Yun Zhang; Adeboye O Osunkoya; David M Schuster
Journal:  Clin Transl Imaging       Date:  2016-12-01

4.  Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016.

Authors:  Kirsten R Carlaw; Henry H Woo
Journal:  Prostate Int       Date:  2017-04-28

Review 5.  Incidental findings in and around the prostate on prostate MRI: a pictorial review.

Authors:  Janki Trivedi; Tom Sutherland; Mark Page
Journal:  Insights Imaging       Date:  2021-03-18

Review 6.  MRI in prostate cancer.

Authors:  Mahyar Ghafoori; Manijeh Alavi; Mounes Aliyari Ghasabeh
Journal:  Iran Red Crescent Med J       Date:  2013-12-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.